Does Valve size Impact Hemodynamic, Left Ventricular Mass Regression and Prosthetic Valve Deterioration with a Sutureless Aortic Valve?

Published:January 23, 2023DOI:
      This paper is only available as a PDF. To read, Please Download here.



      To assess the mid-term clinical outcomes, hemodynamics, left ventricular mass regression and structural valve deterioration in patients implanted with the Perceval aortic sutureless valve across valve sizes.


      Data was obtained from a multicenter European and a U.S. IDE trials. Echocardiography data were analyzed by an echocardiography core lab. Mixed-effects regression model assessed relationship between hemodynamic outcomes, time from procedure and valve sizes. VARC-3 definition for bioprosthetic valve failure was applied.


      The sutureless valve was implanted in 970 patients. The median age was 77.8 years, 57.2% of the patients were female, the median Society of Thoracic Surgeons predicated risk of mortality (STS PROM) was 3.3% [2.1; 6.2], and 33.4 % had concomitant procedures. Median clinical follow-up was 45.7 months [28.2; 76.1]. Small (S) and medium (M) valve sizes were implanted more commonly in women (16.9% versus 1.9% for S and 55.1% versus 19.5% for M, p<0.001). The mean aortic valve gradients decreased significantly post implant and remained stable across all valve sizes throughout the follow up period. All patients were free from severe patient prosthesis mismatch (with EOA/m2 of > 0.8). Significant left ventricular mass regression was documented regardless valve sizes, plateaued at - 9.1% at 5-years. Freedom from structural valve deterioration and reintervention were 95.2% and 96.3% at 5-years and were independent of implanted valve size (p=0.22). VARC-3 Stage 3 bioprosthetic valve failure rate was low, 2.8% at 5 years.


      The Perceval valve demonstrated low and stable mean gradients, significant LV mass regression, low structural valve degeneration and re-intervention rates across all valve sizes.

      Graphical abstract



      AS (aortic stenosis), ASA (acetylsalicylic acid), AVR (aortic valve replacement), CABG (Coronary artery bypass grafting), CE (European conformity), CEC (Clinical Events Committee), CI (confidence intervals), DSMB (Data Safety Monitoring Board), EOA (effective orifice area), FDA (Food and Drug Administration), HR-QoL (health related quality of life), ICU (intensive care unit), IDE (Investigational Device Exemption), IRB (Institutional Review Board), KCCQ (Kansas City Cardiomyopathy Questionnaire), LV (Left Ventricle), LVOT (left ventricle outflow tract), NSVD (non-structural valve dysfunction), NYHA (New York Heart Association), PMI (pace-maker insertion), PVL (paravalvular leak), STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect